EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma1

Ensembl ID : ENSPKIG00000005283
Gene Symbol: GABRG1
3 Cross references
188 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma2

Ensembl ID : ENSPKIG00000001124
Gene Symbol: GABRG2
4 Cross references
136 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma2

Ensembl ID : ENSPKIG00000002728
Gene Symbol: GABRG2
3 Cross references
206 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSPKIG00000013730
Gene Symbol: GABRG3
4 Cross references
276 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSPKIG00000023170
Gene Symbol: GABRG3
4 Cross references
276 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSPKIG00000012447
Gene Symbol: GABBR1
2 Cross references
189 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSPKIG00000011169
Gene Symbol: GABBR1
3 Cross references
189 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 2

Ensembl ID : ENSPKIG00000000392
Gene Symbol: GABBR2
3 Cross references
208 Possible Orthologues:

Gamma-Secretase Subunit Aph-1b

Ensembl ID : ENSPKIG00000000382
Gene Symbol: LOC111847629
3 Cross references
184 Possible Orthologues:

Glucagon Like Peptide 2 Receptor

Ensembl ID : ENSPKIG00000002745
Gene Symbol: GLP2R
2 Cross references
205 Possible Orthologues:

Glucokinase (Hexokinase 4)

Ensembl ID : ENSPKIG00000019104
Gene Symbol: GCK
1 Cross references
210 Possible Orthologues:

Glucosylceramidase Beta 1

Ensembl ID : ENSPKIG00000014818
Gene Symbol: GBA1
3 Cross references
253 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).